NCT03452397View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

April 27, 2018

Study Completion Date

April 27, 2018

Conditions
Dry Eye Disease
Interventions
DRUG

0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)

0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)

DRUG

1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)

1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)

DRUG

2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)

2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)

DRUG

Placebo (vehicle) nasal spray

Placebo (vehicle) nasal spray

Trial Locations (3)

37210

Nashville, Nashville

40206

Louisville, Louisville

01810

Andover, Andover

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT03452397 - Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study) | Biotech Hunter | Biotech Hunter